It is “absolutely fundamental” that manufacturers of cell and gene therapies interact with inspectors from regulatory agencies to understand their expectations around good manufacturing practice, a compliance consultant at CDMO eXmoor pharma says.
Eliza Slawther is a journalist whose work has appeared in Informa publications. She covers a wide range of topics in the pharmaceutical and healthcare industries, including gene therapy, drug development, regulatory strategies, and healthcare policies. Eliza's articles provide insights into the latest developments and trends shaping the pharmaceutical landscape.